This study not only reveals the molecular mechanisms underlying the role of estrogen in promoting development and progression of ER-negative basal-like breast cancers but also identifies a druggable AKT pathway that is activated by estrogen in BRCA1-deficient breast cancers. Here, AKT1 is linked to breast cancer.